144 related articles for article (PubMed ID: 35688655)
1. Deferasirox shows inhibition activity against cervical cancer in vitro and in vivo.
Zhou N; Cui Y; Zhu R; Kuang Y; Ma W; Hou J; Zhu Y; Chen S; Xu X; Tan K; Cao P; Duan X; Fan Y
Gynecol Oncol; 2022 Jul; 166(1):126-137. PubMed ID: 35688655
[TBL] [Abstract][Full Text] [Related]
2. Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo.
Harima H; Kaino S; Takami T; Shinoda S; Matsumoto T; Fujisawa K; Yamamoto N; Yamasaki T; Sakaida I
BMC Cancer; 2016 Aug; 16(1):702. PubMed ID: 27582255
[TBL] [Abstract][Full Text] [Related]
3. The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action.
Lui GY; Obeidy P; Ford SJ; Tselepis C; Sharp DM; Jansson PJ; Kalinowski DS; Kovacevic Z; Lovejoy DB; Richardson DR
Mol Pharmacol; 2013 Jan; 83(1):179-90. PubMed ID: 23074173
[TBL] [Abstract][Full Text] [Related]
4. Deferasirox shows in vitro and in vivo antileukemic effects on murine leukemic cell lines regardless of iron status.
Lee DH; Jang PS; Chung NG; Cho B; Jeong DC; Kim HK
Exp Hematol; 2013 Jun; 41(6):539-46. PubMed ID: 23415674
[TBL] [Abstract][Full Text] [Related]
5. Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox.
Amano S; Kaino S; Shinoda S; Harima H; Matsumoto T; Fujisawa K; Takami T; Yamamoto N; Yamasaki T; Sakaida I
BMC Cancer; 2020 Jul; 20(1):681. PubMed ID: 32698792
[TBL] [Abstract][Full Text] [Related]
6. Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma.
Saeki I; Yamamoto N; Yamasaki T; Takami T; Maeda M; Fujisawa K; Iwamoto T; Matsumoto T; Hidaka I; Ishikawa T; Uchida K; Tani K; Sakaida I
World J Gastroenterol; 2016 Oct; 22(40):8967-8977. PubMed ID: 27833388
[TBL] [Abstract][Full Text] [Related]
7. Synergistic inhibitory effects of deferasirox in combination with decitabine on leukemia cell lines SKM-1, THP-1, and K-562.
Li N; Chen Q; Gu J; Li S; Zhao G; Wang W; Wang Z; Wang X
Oncotarget; 2017 May; 8(22):36517-36530. PubMed ID: 28388554
[TBL] [Abstract][Full Text] [Related]
8. Deferasirox induces cyclin D1 degradation and apoptosis in mantle cell lymphoma in a reactive oxygen species- and GSK3β-dependent mechanism.
Samara A; Shapira S; Lubin I; Shpilberg O; Avigad S; Granot G; Raanani P
Br J Haematol; 2021 Feb; 192(4):747-760. PubMed ID: 33521925
[TBL] [Abstract][Full Text] [Related]
9. Interference of deferasirox with assays for serum iron and serum unsaturated iron binding capacity during iron chelating therapy.
Ikuta K; Ito S; Tanaka H; Sasaki K; Torimoto Y; Fujiya M; Kohgo Y
Clin Chim Acta; 2011 Nov; 412(23-24):2261-6. PubMed ID: 21884685
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload.
Wu D; Wen X; Liu W; Hu H; Ye B; Zhou Y
Drug Des Devel Ther; 2018; 12():1081-1091. PubMed ID: 29760547
[TBL] [Abstract][Full Text] [Related]
11. Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo.
Ford SJ; Obeidy P; Lovejoy DB; Bedford M; Nichols L; Chadwick C; Tucker O; Lui GY; Kalinowski DS; Jansson PJ; Iqbal TH; Alderson D; Richardson DR; Tselepis C
Br J Pharmacol; 2013 Mar; 168(6):1316-28. PubMed ID: 23126308
[TBL] [Abstract][Full Text] [Related]
12. The potential of deferasirox as a novel therapeutic modality in gastric cancer.
Choi JH; Kim JS; Won YW; Uhm J; Park BB; Lee YY
World J Surg Oncol; 2016 Mar; 14():77. PubMed ID: 26965928
[TBL] [Abstract][Full Text] [Related]
13. The iron chelator deferasirox induces apoptosis by targeting oncogenic Pyk2/β-catenin signaling in human multiple myeloma.
Kamihara Y; Takada K; Sato T; Kawano Y; Murase K; Arihara Y; Kikuchi S; Hayasaka N; Usami M; Iyama S; Miyanishi K; Sato Y; Kobune M; Kato J
Oncotarget; 2016 Sep; 7(39):64330-64341. PubMed ID: 27602957
[TBL] [Abstract][Full Text] [Related]
14. Deferasirox has strong anti-leukemia activity but may antagonize theanti-leukemia effect of doxorubicin.
Chang YC; Lo WJ; Huang YT; Lin CL; Feng CC; Lin HT; Cheng HC; Yeh SP
Leuk Lymphoma; 2017 Sep; 58(9):1-12. PubMed ID: 28140713
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of deferasirox for reducing total body and cardiac iron in thalassemia.
Merchant R; Ahmed J; Krishnan P; Jankharia B
Indian Pediatr; 2012 Apr; 49(4):281-5. PubMed ID: 21992861
[TBL] [Abstract][Full Text] [Related]
16. Elevated total iron-binding capacity as a predictor of response to deferasirox therapy in the setting of chronic iron overload.
Watanabe J; Sato K; Horiuchi T; Kato S; Hikota R; Maekawa T; Yamamura T; Kobayashi A; Osawa Y; Kobayashi S; Kimura F
Int J Hematol; 2014 Sep; 100(3):254-9. PubMed ID: 24986748
[TBL] [Abstract][Full Text] [Related]
17. Iron chelator deferasirox inhibits NF-κB activity in hepatoma cells and changes sorafenib-induced programmed cell deaths.
Jomen W; Ohtake T; Akita T; Suto D; Yagi H; Osawa Y; Kohgo Y
Biomed Pharmacother; 2022 Sep; 153():113363. PubMed ID: 35834989
[TBL] [Abstract][Full Text] [Related]
18. Five Years of Deferasirox Therapy for Cardiac Iron in β-Thalassemia Major.
Vlachaki E; Agapidou A; Spanos G; Klonizakis P; Vetsiou E; Mavroudi M; Boura P
Hemoglobin; 2015; 39(5):299-304. PubMed ID: 26177199
[TBL] [Abstract][Full Text] [Related]
19. Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata.
Maurillo L; Breccia M; Buccisano F; Voso MT; Niscola P; Trapè G; Tatarelli C; D'Addosio A; Latagliata R; Fenu S; Piccioni AL; Fragasso A; Aloe Spiriti MA; Refrigeri M; Criscuolo M; Musto P; Venditti A
Eur J Haematol; 2015 Jul; 95(1):52-6. PubMed ID: 25764148
[TBL] [Abstract][Full Text] [Related]
20. Potential anticancer effect of free and nanoformulated Deferasirox for breast cancer treatment:
Abdel-Wahab ND; Kabil MF; El-Sherbiny IM; Salama MF; El-Sayed G; El-Sherbini ES
Drug Dev Ind Pharm; 2024 Mar; 50(3):223-235. PubMed ID: 38305197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
